SEC Form 3 · accession 0000929638-26-002666

enGene Therapeutics Inc. · ENGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Finance and Treasurer

Period of report

Jul 16, 2026

Accepted (ET)

Jul 22, 2026 · 4:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001980845

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares^F1	holding	—	—		—	6,900	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$7.39	holding	—	—	—	—	Jan 29, 2035	Common Shares	45,000	—	D
Stock Option (Right to Buy)^F3	$9.53	holding	—	—	—	—	Jan 30, 2036	Common Shares	13,900	—	D
Stock Option (Right to Buy)^F4	$1.75	holding	—	—	—	—	Jun 16, 2036	Common Shares	105,000	—	D

F1Consists of 6,900 unvested restricted stock units (RSUs) granted to the Reporting Person on January 30, 2026 pursuant to the Issuer's Amended and Restated 2023 Incentive Equity Plan (the "Plan"), which are scheduled to vest annually in substantially equal amounts for four years, commencing January 15, 2027, subject to the Reporting Person's continued service. Each RSU represents a contingent right to receive one common share of the Issuer.
F2Non-qualified stock option grant awarded as an inducement award outside of the Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vested at 25% on January 27, 2026, with the remaining portion to vest monthly in substantially equal amounts for the following 36 months, subject to the Reporting Person's continued service.
F3This option vests monthly in substantially equal amounts for 48 months, commencing January 30, 2026, subject to the Reporting Person's continued service.
F4This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service.

Exhibit 24 - Power of Attorney